Vulvovaginal atrophy is a condition frequently encoutered among menopausal women that often is ignored, remains undiscussed with the physician and the patient adapts the life style is such matter that offers a run from the specific symptomathology. According to the specialized published data, only 25% of the patients with vulvovaginal atrophy receive adequate therapy. The therapeutic perspective is quite extensive but the patient should receive recommendations and try different products until they find one that meets their needs and the one they like best. Proper estrogen therapy leads to a restoration of the acidic, normal vaginal pH, of the vaginal microflora, thickens the epithelium, increases vaginal lubrication and decreases vaginal dryness, also, adverse effects of vaginal estrogen therapy are uncommon. Early active detection of this pathological condition and the provision of an appropriately selected therapy can prevent the progression of the symptomatology and can significantly improve the sexuality of women.
